EYE
National Vision Holdings, Inc. Health Care Ophthalmic Goods Russell 3000
$16.59Close
$1.3BMarket cap
$15.44 – $29.4652-week range
Nov 12, 2026Next report · before the open
Highlights
Strengths
- Earnings growing EPS +41% year on year
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 7 · weaker than 93% of stocks over 12 months
- Far from its high 44% below its 52-week high
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
44%
1wk
down 11.1%
price change
1mo
up 1.3%
price change
12-month return
down 37%
market up 11% ·
its own down 49%
F-score
—
— Not assessed
Altman Z
1.88
Moderate risk
P/E
44.5×
price / earnings
PEG
—
P/E / EPS growth
P/B
1.5×
price / book
Earnings yield
up 3.9%
EBIT / enterprise value
Cheaper than
69%
of the market · cheap
Revenue growth
up 9%
year on year
EPS growth
up 41%
latest quarter · -72 pts
Sales growth
up 3%
latest quarter · -4 pts
ROE
up 4%
return on equity
Free cash margin
up 4%
$73.5M FCF
D/E
0.26
long-term debt / equity
Net debt / EBITDA
1.2×
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Long-term debt down 7% ($0.2B → $0.2B)
Trade setup
ATR%
5.1%
$0.85 a day · 2×ATR $14.90
RS
7 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
1.2×
vs 50-day average
Up/down volume
1.35
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Aug 12, 2026
Last shock
Aug 12, 2026-12% in one session2.8× volumeon results-15% since
Financials
- Net 1%
- Free cash 4%
- Cash
- Long-term debt
| FY2020Jan 2, 2021 | FY2021Jan 1, 2022 | FY2022Dec 31, 2022 | FY2023Dec 30, 2023 | FY2024Dec 28, 2024 | FY2025Jan 3, 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | $2.1B | $1.6B | $1.8B | $1.8B | $2.0B |
| Operating income | $87.0M | $174.9M | $52.8M | $24.5M | -$10.4M | $58.8M |
| Net income | $36.3M | $128.2M | $42.1M | -$65.9M | -$28.5M | $29.6M |
| Net margin | 2% | 6% | 3% | -4% | -2% | 1% |
| Earnings per share | $0.44 | $1.33 | $0.52 | -$0.84 | -$0.36 | $0.37 |
| Free cash flow | $158.2M | $163.4M | $5.7M | $58.3M | $38.1M | $73.5M |
| Free cash margin | 9% | 8% | 0% | 3% | 2% | 4% |
| Cash | $373.9M | $305.8M | $229.4M | $149.9M | $73.9M | $38.7M |
| Long-term debt | $624.6M | $543.6M | $546.2M | $437.7M | $239.1M | $223.2M |
| Shareholders' equity | $906.5M | $926.0M | $901.1M | $829.4M | $816.3M | $869.5M |
| Shares outstanding | 81.24m | 81.41m | 78.99m | 78.31m | 78.78m | 79.42m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 13, 2026 | Quarterly ↗ | Jul 4, 2026 | 40d |
| May 14, 2026 | Quarterly ↗ | Apr 4, 2026 | 40d |
| Mar 4, 2026 | Annual ↗ | Jan 3, 2026 | 60d |
| Nov 6, 2025 | Quarterly ↗ | Sep 27, 2025 | 40d |
| Aug 7, 2025 | Quarterly ↗ | Jun 28, 2025 | 40d |
| May 8, 2025 | Quarterly ↗ | Mar 29, 2025 | 40d |
| Feb 26, 2025 | Annual ↗ | Dec 28, 2024 | 60d |
| Nov 6, 2024 | Quarterly ↗ | Sep 28, 2024 | 39d |
| Aug 7, 2024 | Quarterly ↗ | Jun 29, 2024 | 39d |
| May 8, 2024 | Quarterly ↗ | Mar 30, 2024 | 39d |
| Feb 27, 2024 | Annual ↗ | Dec 30, 2023 | 59d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 12, 2026 | Results ↗ |
| Jun 22, 2026 | Shareholder vote ↗ |
| Jun 3, 2026 | Regulation FD ↗ |
| May 13, 2026 | Results ↗ |
| Mar 4, 2026 | Results ↗ |
| Dec 16, 2025 | Material agreement ↗ |
| Nov 5, 2025 | Results ↗ |
| Aug 6, 2025 | Results ↗ |
| Aug 4, 2025 | Director or officer change ↗ |
| Jun 23, 2025 | Shareholder vote ↗ |
| May 7, 2025 | Results ↗ |
| Apr 29, 2025 | Director or officer change · Regulation FD ↗ |